Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Cryopyrin-Associated Periodic Syndromes Affected by NLRP3 Mutation

Lara C. Pullen, PhD  |  November 7, 2014

The immune system has various extracellular strategies for clearing infectious agents and recovering homeostasis. A defect in one of these strategies can result in vulnerability to infection, chronic inflammation and/or autoinflammatory disease.

Cryopyrin-associated periodic syndromes (CAPS) is a spectrum of autoinflammatory syndromes that occur as a result of a rare, heterozygous, gain-of-function mutation in the inflammasome NLRP3. Patients with CAPS have pathological concentrations of C-reactive proteins in their serum, as well as an abundance of extracellular oligomeric ASC+ particles compared with the serum of healthy donors. Although IL-1β appears to drive the clinical phenotype of CAPS, patients don’t consistently have a higher serum concentration of IL-1β than healthy controls.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Traditionally, the NLRP3 inflammasome has been seen as an oligomer with the core sensor NLRP3 and an ASC adaptor. When the two come together, they recruit the protease caspase-1. Caspase-1 controls its own release as well as the release of various leaderless proteins such as the cytokines IL-1β and IL-18. Caspase-1 also induces pyroptosis in macrophages, causing the macrophages to quickly lose plasma membrane integrity and release intracellular proteins, such as the enzyme, lactate dehydrogenase.

A new study expands on this understanding of the NLRP3 inflammasome and indicates that NLRP3 amplifies the inflammatory response through its role as an extracellular oligomeric complex.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers Alberto Baroja-Mazo, PhD, postdoctoral fellow at the Clinical University Hospital Virgen de la Arrixaca in Murcia, Spain, and colleagues describe their model in the August issue of Nature Immunology.1 They write, “In this study, we found that activation of inflammasomes led to the release of functional oligomeric inflammasome particles containing both NLRP3 and ASC that acted as danger signals to amplify inflammation by promoting the activation of caspase-1 extracellularly and in surrounding macrophages following internalization of the particles. Caspase-1 activity was necessary for the release of inflammasome particles from activated macrophages during pyroptosis. The released, extracellular caspase-1 was active and was able to mature pro-IL-1.”

The investigators began their study by determining that activation of the NLRP3, NLRP1 or AIM2 inflammasomes leads to the release of ASC, NLRP3, IL-1β and caspase-1 p10. Activated caspase-1 was able to process pro-IL-1β. After the inflammasomes were activated, NLRP3 continued to be released even after the inhibition of caspase-1. After 10–30 minutes of activation of the NLRP3 inflammasome, extracellular ASC became oligomeric, aggregating into inflammasome oligomeric specks. The ASC specks were able to further increase caspase-1 activity. Thus, an increase in ASC particles over the course of three hours was associated with a continued increase in the release of IL-1β.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsResearch Rheum Tagged with:autoinflammatory diseaseCAPSCryopyrin-Associated Periodic SyndromesPullenrheumatology

Related Articles

    The Expanded Role of the Inflammasome in Human Disease

    August 1, 2010

    Exploring advances, evaluating what remains to be done

    Cryopyrin-Associated Periodic Syndromes: Difficult to Recognize, Diagnose, Treat

    October 1, 2014

    Two case studies demonstrate the difficulty, delay in recognizing this rare autoinflammatory disease

    POP1-Based Treatments May Reduce Inflammation

    September 21, 2015

    A recent study analyzed inflammasome response, finding the POP1 PYRIN domain protein acts to decrease excessive inflammatory responses and prevent systemic inflammation. Researchers ultimately developed a drug based on POP1 and found it reduced inflammation in mice…

    Communications Line to the Top

    May 1, 2009

    The Affiliate Society Council brings local concerns to the ACR leadership

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences